Strategy
MSTR
MARA Holdings
MARA
NVIDIA
NVDA
Tesla
TSLA
Coinbase
COIN
US Stock MarketDetailed Quotes
VRTX Vertex Pharmaceuticals
- 479.790
- +5.290+1.11%
Close Feb 28 16:00 ET
- 479.700
- -0.090-0.02%
Post 20:01 ET
123.21BMarket Cap-230.67P/E (TTM)
484.980High474.010Low2.47MVolume479.900Open474.500Pre Close1.18BTurnover0.97%Turnover RatioLossP/E (Static)256.79MShares519.88052wk High7.51P/B122.79BFloat Cap377.85052wk Low--Dividend TTM255.92MShs Float519.880Historical High--Div YieldTTM2.31%Amplitude7.250Historical Low479.265Avg Price1Lot Size
About Vertex Pharmaceuticals Company
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Company Profile
SymbolVRTX
Company NameVertex Pharmaceuticals
Listing DateJul 4, 1991
Issue Price13.75
Founded1989
CEODr. Reshma Kewalramani, M.D.
MarketNASDAQ
Employees6100
Fiscal Year Ends12-31
Address50 Northern Avenue
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02210
Phone1-617-341-6100
Websitehttp://www.vrtx.com
Company Executives
- Name
- Position
- Salary
- Dr. Reshma Kewalramani, M.D.
- Director, President and Chief Executive Officer
- 20.59M
- Jonathan Biller
- Executive Vice President and Chief Legal Officer
- --
- Charles F. Wagner, Jr
- Executive Vice President and Chief Financial Officer
- 7.37M
- Stuart A. Arbuckle
- Executive Vice President and Chief Operating Officer
- 9.00M
- Carmen Bozic
- Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
- --
- Kristen Ambrose
- Senior Vice President and Chief Accounting Officer
- --
- Dr. Ourania Tatsis, PhD
- Executive Vice President and Chief Regulatory and Quality Officer
- --
- Amit K. Sachdev, J.D.
- Executive Vice President and Chief Patient and External Affairs Officer
- --
- Dr. E Morrow Atkinson, III, PhD
- Executive Vice President, Chief Technical Operations Officer and Head, Biopharmaceutical Science and Manufacturing Operations
- --
- Dr. David Altshuler
- Executive Vice President and Chief Scientific Officer
- 6.54M
- Duncan J. McKechnie
- Senior Vice President and Head, North America Commercial Team
- --
- Dr. Jeffrey M Leiden, PhD
- Executive Chairman of the Board
- 6.60M
- Diana L. McKenzie
- Independent Director
- 553.11K
- Lloyd A. Carney
- Independent Director
- 559.79K
- Suketu Upadhyay
- Independent Director
- 544.66K
- Dr. Alan M. Garber, M.D.,PhD
- Independent Director
- 537.63K
- Bruce I. Sachs
- Lead Independent Director
- 600.04K
- Nancy A. Thornberry
- Independent Director
- 407.65K
- Dr. Jennifer Schneider, M.D.
- Independent Director
- --
- Michel Lagarde
- Independent Director
- 449.08K
- Dr. Sangeeta N. Bhatia, PhD
- Independent Director
- 550.31K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
